BAY 11-7082, a nuclear factor-κB inhibitor, induces apoptosis and S phase arrest in gastric cancer cells

Journal of Gastroenterology

Volumn 49, Issue 5, 2014, Pages 864-874

  Chen, Ling ^a   Ruan, Yuanyuan ^a   Wang, Xuefei ^a   Min, Lingqiang ^a   Shen, Zhenbin ^a   Sun, Yihong ^a   Qin, Xinyu ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Apoptosis; BAY 11 7082; Cell cycle; Gastric cancer; Nuclear factor B

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; CHOLECYSTOKININ OCTAPEPTIDE; CYCLIN A; CYCLIN DEPENDENT KINASE 2; LIPOCORTIN 5; PROPIDIUM IODIDE; 3-(4-METHYLPHENYLSULFONYL)-2-PROPENENITRILE; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRILE; SULFONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE PROGRESSION; CELL VIABILITY; CELL VIABILITY ASSAY; CONTROLLED STUDY; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; S PHASE CELL CYCLE CHECKPOINT; STOMACH CANCER; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; COMPARATIVE STUDY; DOWN REGULATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; NUDE MOUSE; PATHOLOGY; STOMACH NEOPLASMS; TUMOR CELL LINE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NF-KAPPA B; NITRILES; S PHASE CELL CYCLE CHECKPOINTS; STOMACH NEOPLASMS; SULFONES; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901431337     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0848-4     Document Type: Article

References (63)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010;17:3077-9.
3. Oshima T, Masuda M. Molecular targeted agents for gastric and gastroesophageal junction cancer. Surg Today. 2012;42:313-27.
4. DiDonato JA, Mercurio F, Karin M. NF-kappaB and the link between inflammation and cancer. Immunol Rev. 2012;246:379-400.
5. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301-10. (Pubitemid 37328783)
6. Perkins ND. The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer. 2012;12:121-32.
7. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell. 2002;109(Suppl):S81-96.
8. Kanarek N, Ben-Neriah Y. Regulation of NF-kappaB by ubiquitination and degradation of the IkappaBs. Immunol Rev. 2012;246:77-94.
9. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005;5:297-309. (Pubitemid 40488635)
10. Sasaki N, Morisaki T, Hashizume K, Yao T, Tsuneyoshi M, Noshiro H, et al. Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res. 2001;7:4136-42. (Pubitemid 34044638)
11. Wu L, Pu Z, Feng J, Li G, Zheng Z, Shen W. The ubiquitin-proteasome pathway and enhanced activity of NF-kappaB in gastric carcinoma. J Surg Oncol. 2008;97:439-44. (Pubitemid 351466388)
12. Kang MJ, Ryu BK, Lee MG, Han J, Lee JH, Ha TK, et al. NF-kappaB activates transcription of the RNA-binding factor HuR, via PI3 K-AKT signaling, to promote gastric tumorigenesis. Gastroenterology. 2008;135:2030-42, 2042.e1-3.
13. Liu CA, Wang MJ, Chi CW, Wu CW, Chen JY. Rho/Rhotekin-mediated NF-kappaB activation confers resistance to apoptosis. Oncogene. 2004;23:8731-42.
14. Sakamoto K, Hikiba Y, Nakagawa H, Hayakawa Y, Yanai A, Akanuma M, et al. Inhibitor of kappaB kinase beta regulates gastric carcinogenesis via interleukin-1alpha expression. Gastroenterology. 2010;139(226-238):e226.
15. Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med. 2007;13:470-6. (Pubitemid 46559833)
16. Liu X, Wang X, Zhang J, Lam EK, Shin VY, Cheng AS, et al. Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis. Oncogene. 2010;29:442-50.
17. Cho SJ, Park JW, Kang JS, Kim WH, Juhnn YS, Lee JS, et al. Nuclear factor-kappaB dependency of doxorubicin sensitivity in gastric cancer cells is determined by manganese superoxide dismutase expression. Cancer Sci. 2008;99:1117-24. (Pubitemid 351676622)
18. Zanotto-Filho A, Braganhol E, Schroder R, de Souza LH, Dalmolin RJ, Pasquali MA, et al. NFkappaB inhibitors induce cell death in glioblastomas. Biochem Pharmacol. 2011;81:412-24.
19. Meng Z, Lou S, Tan J, Xu K, Jia Q, Zheng W. Nuclear factorkappa B inhibition can enhance apoptosis of differentiated thyroid cancer cells induced by 131I. PLoS ONE. 2012;7:e33597.
20. Nakabayashi H, Shimizu K. Involvement of Akt/NF-kappaB pathway in antitumor effects of parthenolide on glioblastoma cells in vitro and in vivo. BMC Cancer. 2012;12:453.
21. Buontempo F, Chiarini F, Bressanin D, Tabellini G, Melchionda F, Pession A, et al. Activity of the selective IkappaB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a. Cell Cycle. 2012;11:2467-75.
22. Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD, et al. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. Mol Cancer Ther. 2007;6:1973-82. (Pubitemid 47052487)
23. Jakubowska-Mucka A, Sienko J, Zapala L, Wolny R, Lasek W. Synergistic cytotoxic effect of sulindac and pyrrolidine dithiocarbamate against ovarian cancer cells. Oncol Rep. 2012;27:1245-50.
24. Li Q, Yu YY, Zhu ZG, Ji YB, Zhang Y, Liu BY, et al. Effect of NF-kappaB constitutive activation on proliferation and apoptosis of gastric cancer cell lines. Eur Surg Res. 2005;37:105-10. (Pubitemid 40864173)
25. Fujita T, Doihara H, Washio K, Ino H, Murakami M, Naito M, et al. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells. Anticancer Drugs. 2007;18:677-86. (Pubitemid 47343660)
26. Zaidi SF, Yamamoto T, Refaat A, Ahmed K, Sakurai H, Saiki I, et al. Modulation of activation-induced cytidine deaminase by curcumin in Helicobacter pylori-infected gastric epithelial cells. Helicobacter. 2009;14:588-95.
27. Mino K, Ozaki M, Nakanishi K, Haga S, Sato M, Kina M, et al. Inhibition of nuclear factor-kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion. Cancer Sci. 2011;102:1052-8.
28. Sohma I, Fujiwara Y, Sugita Y, Yoshioka A, Shirakawa M, Moon JH, et al. Parthenolide, an NF-kappaB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer. Cancer Genomics Proteomics. 2011;8:39-47.
29. Ruan Y, Sun L, Hao Y, Wang L, Xu J, Zhang W, et al. Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma. J Clin Invest. 2012;122:2554-66.
30. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Murcia JM. Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem. 1998;273:33533-9. (Pubitemid 29005737)
31. Lipton SA, Bossy-Wetzel E. Dueling activities of AIF in cell death versus survival: DNA binding and redox activity. Cell. 2002;111:147-50. (Pubitemid 35292433)
32. Kurokawa M, Kornbluth S. Caspases and kinases in a death grip. Cell. 2009;138:838-54.
33. Fuchs Y, Steller H. Programmed cell death in animal development and disease. Cell. 2011;147:742-58.
34. Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11:621-32.
35. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003;36:131-49. (Pubitemid 36808270)
36. Fuchs O. Transcription factor NF-kappaB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies. Curr Mol Pharmacol. 2010;3:98-122.
37. Kim HJ, Hawke N, Baldwin AS. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ. 2006;13:738-47.
38. Murata T, Shimada M, Kadono H, Sakakibara S, Yoshino T, Masuda T, et al. Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 2: improvement of in vitro activity. Bioorg Med Chem Lett. 2004;14:4013-7. (Pubitemid 38844415)
39. Ziegelbauer K, Gantner F, Lukacs NW, Berlin A, Fuchikami K, Niki T, et al. A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol. 2005;145:178-92. (Pubitemid 40756522)
40. Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M, et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res. 2005;11:28-40. (Pubitemid 40075775)
41. Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC. Proteasome inhibition as a new therapeutic principle in hematological malignancies. Curr Drug Targets. 2006;7:1341-7. (Pubitemid 44509698)
42. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem. 1997;272:21096-103. (Pubitemid 27373968)
43. Fernandez-Majada V, Aguilera C, Villanueva A, Vilardell F, Robert-Moreno A, Aytes A, et al. Nuclear IKK activity leads to dysregulated notch-dependent gene expression in colorectal cancer. Proc Natl Acad Sci USA. 2007;104:276-81. (Pubitemid 46068022)
44. Hernandez-Vargas H, Rodriguez-Pinilla SM, Julian-Tendero M, Sanchez-Rovira P, Cuevas C, Anton A, et al. Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat. 2007;102:157-72. (Pubitemid 46452170)
45. Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood. 2000;96:2537-42.
46. Mori N, Yamada Y, Ikeda S, Yamasaki Y, Tsukasaki K, Tanaka Y, et al. Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood. 2002;100:1828-34. (Pubitemid 34925163)
47. Pickering BM, de Mel S, Lee M, Howell M, Habens F, Dallman CL, et al. Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene. 2007;26:1166-77.
48. Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene. 2001;20:7342-51. (Pubitemid 33078205)
49. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death - a new approach to cancer therapy. J Clin Invest. 2005;115:2625-32. (Pubitemid 41434385)
50. Lupino E, Buccinna B, Ramondetti C, Lomartire A, De Marco G, Ricotti E, et al. In CD28-costimulated human naive CD4+ T cells, I-kappaB kinase controls the expression of cell cycle regulatory proteins via interleukin-2-independent mechanisms. Immunology. 2010;131:231-41.
51. Topping RJ, Jones MM. Optimal dithiocarbamate structure for immunomodulator action. Med Hypotheses. 1988;27:55-7.
52. Beligni MV, Fath A, Bethke PC, Lamattina L, Jones RL. Nitric oxide acts as an antioxidant and delays programmed cell death in barley aleurone layers. Plant Physiol. 2002;129:1642-50. (Pubitemid 34923228)
53. Iseki A, Kambe F, Okumura K, Hayakawa T, Seo H. Regulation of thyroid follicular cell function by intracellular redox-active copper. Endocrinology. 2000;141:4373-82. (Pubitemid 32055111)
54. Zheng X, Chang RL, Cui XX, Avila G, Huang MT, Liu Y, et al. Inhibition of NF-kappaB by (E)3-[(4-methylphenyl)-sulfonyl]-2-propenenitrile (BAY11-7082; BAY) is associated with enhanced 12-O-tetradecanoylphorbol-13-acetate-induced growth suppression and apoptosis in human prostate cancer PC-3 cells. Int J Oncol. 2008;32:257-64. (Pubitemid 351176085)
55. Xue W, Meylan E, Oliver TG, Feldser DM, Winslow MM, Bronson R, et al. Response and resistance to NF-kappaB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov. 2011;1:236-47.
56. Li B, Li YY, Tsao SW, Cheung AL. Targeting NF-kappaB signaling pathway suppresses tumor growth, angiogenesis, and metastasis of human esophageal cancer. Mol Cancer Ther. 2009;8:2635-44.
57. Scaife CL, Kuang J, Wills JC, Trowbridge DB, Gray P, Manning BM, et al. Nuclear factor kappaB inhibitors induce adhesion-dependent colon cancer apoptosis: implications for metastasis. Cancer Res. 2002;62:6870-8. (Pubitemid 35424075)
58. Keller SA, Hernandez-Hopkins D, Vider J, Ponomarev V, Hyjek E, Schattner EJ, et al. NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood. 2006;107:3295-302.
59. Miyamoto R, Ito T, Nomura S, Amakawa R, Amuro H, Katashiba Y, et al. Inhibitor of IkappaB kinase activity, BAY 11-7082, interferes with interferon regulatory factor 7 nuclear translocation and type I interferon production by plasmacytoid dendritic cells. Arthritis Res Ther. 2010;12:R87.
60. Jia YT, Ma B, Wei W, Xu Y, Wang Y, Tang HT, et al. Sustained activation of nuclear factor-kappaB by reactive oxygen species is involved in the pathogenesis of stress-induced gastric damage in rats. Crit Care Med. 2007;35:1582-91. (Pubitemid 46809324)
61. Kumar A, Negi G, Sharma SS. Suppression of NF-kappaB and NF-kappaB regulated oxidative stress and neuroinflammation by BAY 11-7082 (IkappaB phosphorylation inhibitor) in experimental diabetic neuropathy. Biochimie. 2012;94:1158-65.
62. Piechota A, Goraca A. Influence of nuclear factor-kappaB inhibition on endothelin-1 induced lung edema and oxidative stress in rats. J Physiol Pharmacol. 2011;62:183-8.
63. Shah MA, Power DG, Kindler HL, Holen KD, Kemeny MM, Ilson DH, et al. A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Invest New Drugs. 2011;29:1475-81.